Patents by Inventor Ann C. Raddant

Ann C. Raddant has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11325967
    Abstract: The present invention is directed to methods of inhibiting or preventing photophobia in subjects in need thereof using anti-CGRP antibodies or antibody fragments that inhibit photophobia, especially CGRP-associated photophobia. These antibodies and fragments are useful in treating different disorders associated with photophobia such as migraine, cluster headaches and the like. The present invention also provides assays using transgenic Nestin/Ramp1 rodents, utilizing a CGRP model light aversive behavior model for identifying therapeutically effective anti-CGRP antibodies and fragments thereof having binding specificity for CGRP which inhibit or prevent photophobia in subjects in need thereof. The present invention is specifically directed to methods for identifying therapeutically effective antibodies and fragments thereof having binding specificity for CGRP that may be used to treat CGRP associated disorders such as migraine.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: May 10, 2022
    Assignees: H. LUNDBECK A/S, THE UNIVERSITY OF IOWA RESEARCH FOUNDATION
    Inventors: Andrew F. Russo, Eric A. Kaiser, Ana Recober, Adisa Kuburas, Ann C. Raddant, Brian R. Kovacevich, John Latham, Jeffrey T. L. Smith, Leon F. Garcia-Martinez
  • Patent number: 11027018
    Abstract: The present invention is directed to methods for treating diarrhea, both chronic or acute forms, by the administration of a therapeutically or prophylactically effective amount of antibodies and fragments thereof having binding specificity for CGRP. In particular the methods prevent or reduce diarrhea in conditions or treatments resulting in elevated CGRP levels, e.g., in the GI tract (colon) that are associated with diarrhea and/or improper electrolyte and fluid excretion from the bowel or urinary system. More specifically, this invention relates to treatments using the anti-CGRP antibodies and fragments described herein, and binding fragments thereof.
    Type: Grant
    Filed: February 13, 2019
    Date of Patent: June 8, 2021
    Assignees: The University of Iowa Research Foundation, H. LUNDBECK A/S
    Inventors: Andrew F. Russo, Eric A. Kaiser, Ana Recober, Adisa Kuburas, Ann C. Raddant, Brian R. Kovacevich, John Latham, Jeffrey T. L. Smith, Leon F. Garcia-Martinez
  • Patent number: 10765746
    Abstract: The present invention is directed to methods for treating diarrhea, both chronic or acute forms, by the administration of a therapeutically or prophylactically effective amount of antibodies and fragments thereof having binding specificity for CGRP. In particular the methods prevent or reduce diarrhea in conditions or treatments resulting in elevated CGRP levels, e.g., in the GI tract (colon) that are associated with diarrhea and/or improper electrolyte and fluid excretion from the bowel or urinary system. More specifically, this invention relates to treatments using the anti-CGRP antibodies and fragments described herein, and binding fragments thereof.
    Type: Grant
    Filed: November 20, 2017
    Date of Patent: September 8, 2020
    Assignees: ALDERBIO HOLDINGS LLC, THE UNIVERSITY OF IOWA RESEARCH FOUNDATION
    Inventors: Andrew F. Russo, Eric A. Kaiser, Ana Recober, Adisa Kuburas, Ann C. Raddant, Brian R. Kovacevich, John Latham, Jeffrey T. L. Smith, Leon F. Garcia-Martinez
  • Publication number: 20190367590
    Abstract: The present invention is directed to methods of inhibiting or preventing photophobia in subjects in need thereof using anti-CGRP antibodies or antibody fragments that inhibit photophobia, especially CGRP-associated photophobia. These antibodies and fragments are useful in treating different disorders associated with photophobia such as migraine, cluster headaches and the like. The present invention also provides assays using transgenic Nestin/Ramp1 rodents, utilizing a CGRP model light aversive behavior model for identifying therapeutically effective anti-CGRP antibodies and fragments thereof having binding specificity for CGRP which inhibit or prevent photophobia in subjects in need thereof. The present invention is specifically directed to methods for identifying therapeutically effective antibodies and fragments thereof having binding specificity for CGRP that may be used to treat CGRP associated disorders such as migraine.
    Type: Application
    Filed: April 18, 2019
    Publication date: December 5, 2019
    Inventors: Andrew F. Russo, Eric A. Kaiser, Ana Recober, Adisa Kuburas, Ann C. Raddant, Brian R. Kovacevich, John Latham, Jeffrey T.L. Smith, Leon F. Garcia-Martinez
  • Publication number: 20190240331
    Abstract: The present invention is directed to methods for treating diarrhea, both chronic or acute forms, by the administration of a therapeutically or prophylactically effective amount of antibodies and fragments thereof having binding specificity for CGRP. In particular the methods prevent or reduce diarrhea in conditions or treatments resulting in elevated CGRP levels, e.g., in the GI tract (colon) that are associated with diarrhea and/or improper electrolyte and fluid excretion from the bowel or urinary system. More specifically, this invention relates to treatments using the anti-CGRP antibodies and fragments described herein, and binding fragments thereof.
    Type: Application
    Filed: February 13, 2019
    Publication date: August 8, 2019
    Inventors: Andrew F. Russo, Eric A. Kaiser, Ana Recober, Adisa Kuburas, Ann C. Raddant, Brian R. Kovacevich, John Latham, Jeffrey T.L. Smith, Leon F. Garcia-Martinez
  • Patent number: 10266587
    Abstract: The present invention is directed to methods of inhibiting or preventing photophobia in subjects in need thereof using anti-CGRP antibodies or antibody fragments that inhibit photophobia, especially CGRP-associated photophobia. These antibodies and fragments are useful in treating different disorders associated with photophobia such as migraine, cluster headaches and the like. The present invention also provides assays using transgenic Nestin/Ramp1 rodents, utilizing a CGRP model light aversive behavior model for identifying therapeutically effective anti-CGRP antibodies and fragments thereof having binding specificity for CGRP which inhibit or prevent photophobia in subjects in need thereof. The present invention is specifically directed to methods for identifying therapeutically effective antibodies and fragments thereof having binding specificity for CGRP that may be used to treat CGRP associated disorders such as migraine.
    Type: Grant
    Filed: June 13, 2017
    Date of Patent: April 23, 2019
    Assignees: ALDERBIO HOLDINGS LLC, THE UNIVERSITY OF IOWA FOUNDATION
    Inventors: Andrew F. Russo, Eric A. Kaiser, Ana Recober, Adisa Kuburas, Ann C. Raddant, Brian R. Kovacevich, John Latham, Jeffrey T. L. Smith, Leon F. Garcia-Martinez
  • Publication number: 20180161434
    Abstract: The present invention is directed to methods for treating diarrhea, both chronic or acute forms, by the administration of a therapeutically or prophylactically effective amount of antibodies and fragments thereof having binding specificity for CGRP. In particular the methods prevent or reduce diarrhea in conditions or treatments resulting in elevated CGRP levels, e.g., in the GI tract (colon) that are associated with diarrhea and/or improper electrolyte and fluid excretion from the bowel or urinary system. More specifically, this invention relates to treatments using the anti-CGRP antibodies and fragments described herein, and binding fragments thereof.
    Type: Application
    Filed: November 20, 2017
    Publication date: June 14, 2018
    Inventors: Andrew F. RUSSO, Eric A. KAISER, Ana RECOBER, Adisa KUBURAS, Ann C. RADDANT, Brian R. KOVACEVICH, John LATHAM, Jeffrey T.L. SMITH, Leon F. GARCIA-MARTINEZ
  • Patent number: 9855332
    Abstract: The present invention is directed to methods for treating diarrhea, both chronic or acute forms, by the administration of a therapeutically or prophylactically effective amount of antibodies and fragments thereof having binding specificity for CGRP. In particular the methods prevent or reduce diarrhea in conditions or treatments resulting in elevated CGRP levels, e.g., in the GI tract (colon) that are associated with diarrhea and/or improper electrolyte and fluid excretion from the bowel or urinary system. More specifically, this invention relates to treatments using the anti-CGRP antibodies and fragments described herein, and binding fragments thereof.
    Type: Grant
    Filed: May 21, 2012
    Date of Patent: January 2, 2018
    Assignee: ALDERBIO HOLDINGS LLC
    Inventors: Andrew F. Russo, Eric A. Kaiser, Ana Recober, Adisa Kuburas, Ann C. Raddant, Brian Robert Kovacevich, John A. Latham, Jeffrey T. L. Smith, Leon F. Garcia-Martinez
  • Publication number: 20170342141
    Abstract: The present invention is directed to methods of inhibiting or preventing photophobia in subjects in need thereof using anti-CGRP antibodies or antibody fragments that inhibit photophobia, especially CGRP-associated photophobia. These antibodies and fragments are useful in treating different disorders associated with photophobia such as migraine, cluster headaches and the like. The present invention also provides assays using transgenic Nestin/Ramp1 rodents, utilizing a CGRP model light aversive behavior model for identifying therapeutically effective anti-CGRP antibodies and fragments thereof having binding specificity for CGRP which inhibit or prevent photophobia in subjects in need thereof. The present invention is specifically directed to methods for identifying therapeutically effective antibodies and fragments thereof having binding specificity for CGRP that may be used to treat CGRP associated disorders such as migraine.
    Type: Application
    Filed: June 13, 2017
    Publication date: November 30, 2017
    Inventors: Andrew F. RUSSO, Eric A. Kaiser, Ana Recober, Adisa Kuburas, Ann C. Raddant, Brian R. Kovacevich, John Latham, Jeffrey T.L. Smith, Leon F. Garcia-Martinez
  • Patent number: 9708393
    Abstract: The present invention is directed to methods of inhibiting or preventing photophobia in subjects in need thereof using anti-CGRP antibodies or antibody fragments that inhibit photophobia, especially CGRP-associated photophobia. These antibodies and fragments are useful in treating different disorders associated with photophobia such as migraine, cluster headaches and the like.
    Type: Grant
    Filed: May 21, 2012
    Date of Patent: July 18, 2017
    Assignee: ALDERBIO HOLDINGS LLC
    Inventors: Andrew F. Russo, Eric A. Kaiser, Ana Recober, Adisa Kuburas, Ann C. Raddant, Brian Robert Kovacevich, John A. Latham, Jeffrey T. L. Smith, Leon F. Garcia-Martinez
  • Publication number: 20120294822
    Abstract: The present invention is directed to methods for treating diarrhea, both chronic or acute forms, by the administration of a therapeutically or prophylactically effective amount of antibodies and fragments thereof having binding specificity for CGRP. In particular the methods prevent or reduce diarrhea in conditions or treatments resulting in elevated CGRP levels, e.g., in the GI tract (colon) that are associated with diarrhea and/or improper electrolyte and fluid excretion from the bowel or urinary system. More specifically, this invention relates to treatments using the anti-CGRP antibodies and fragments described herein, and binding fragments thereof.
    Type: Application
    Filed: May 21, 2012
    Publication date: November 22, 2012
    Inventors: Andrew F. Russo, Eric A. Kaiser, Ana Recober, Adisa Kuburas, Ann C. Raddant, Brian Robert Kovacevich, John A. Latham, Jeffrey T.L. Smith, Leon F. Garcia-Martinez
  • Publication number: 20120294802
    Abstract: The present invention is directed to methods of inhibiting or preventing photophobia in subjects in need thereof using anti-CGRP antibodies or antibody fragments that inhibit photophobia, especially CGRP-associated photophobia. These antibodies and fragments are useful in treating different disorders associated with photophobia such as migraine, cluster headaches and the like.
    Type: Application
    Filed: May 21, 2012
    Publication date: November 22, 2012
    Inventors: Andrew F. Russo, Eric A. Kaiser, Ana Recober, Adisa Kuburas, Ann C. Raddant, Brian Robert Kovacevich, John A. Latham, Jeffrey T.L. Smith, Leon F. Garcia-Martinez